SCHEMBL474752

SCHEMBL474752

CC(=O)Nc1ccc(NN)cc1

nearest known ligand 0.67

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 3/20 0.67
L3MBTL1 Q9Y468 2/20 0.67
HTT P42858 1/20 0.67
KMT2A Q03164 6/20 0.64
MEN1 O00255 4/20 0.64
CA1 P00915 4/20 0.64
CA2 P00918 4/20 0.64
CA9 Q16790 4/20 0.64
ALDH1A1 P00352 4/20 0.64
MAPT P10636 3/20 0.64
CA12 O43570 3/20 0.64
TDP1 Q9NUW8 1/20 0.64
BRD4 O60885 1/20 0.64
NR1I2 O75469 1/20 0.64
MB P02144 1/20 0.64
CYP1A1 P04798 1/20 0.64
CA3 P07451 1/20 0.64
CYP3A4 P08684 1/20 0.64
RARG P13631 1/20 0.64
TSHR P16473 1/20 0.64

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL8530273 0.98 SMN1; SMN2 (0.64) SMN1; SMN2L3MBTL1HTTKMT2AMEN1
SCHEMBL861674 0.87 SMN1; SMN2 (0.84) SMN1; SMN2L3MBTL1HTTKMT2AMEN1
SCHEMBL9771268 0.85 POLB (0.53) SMN1; SMN2L3MBTL1HTTKMT2AMEN1
SCHEMBL92049 0.81 PKM (0.75) SMN1; SMN2L3MBTL1HTTKMT2AMEN1
SCHEMBL11925383 0.81 SMN1; SMN2 (0.67) SMN1; SMN2L3MBTL1HTTKMT2AMEN1
SCHEMBL11158565 0.80 MAPT (0.83) SMN1; SMN2L3MBTL1HTTKMT2AMEN1
SCHEMBL3818831 0.80 SMN1; SMN2 (1.00) SMN1; SMN2L3MBTL1HTTKMT2AMEN1
Hydrochloric Acid SCHEMBL4819296 0.79 PKM (0.72) SMN1; SMN2L3MBTL1HTTKMT2AMEN1
SCHEMBL2924725 0.79 CACNA1B (0.65) SMN1; SMN2L3MBTL1HTTKMT2AMEN1
SCHEMBL1303329 0.79 ALDH1A1 (0.72) SMN1; SMN2L3MBTL1KMT2AMEN1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220356182-A1 INHIBITORS OF HEPATITIS C VIRUS REPLICATION MERCK SHARP & DOHME CORP. (US) 2022-11-10 US disclosed
US-20220356182-A1 INHIBITORS OF HEPATITIS C VIRUS REPLICATION MERCK SHARP & DOHME CORP. (US) 2022-11-10 US disclosed
CN-108586369-B Process for producing phenyltriazine compound and process for producing phenylpyridine compound 中国科学院长春应用化学研究所 2021-08-17 CN disclosed
US-11053243-B2 Inhibitors of hepatitis C virus replication MERCK SHARP & DOHME CORP. (US) 2021-07-06 US disclosed
US-11053243-B2 Inhibitors of hepatitis C virus replication MERCK SHARP & DOHME CORP. (US) 2021-07-06 US disclosed
US-20200262836-A1 INHIBITORS OF HEPATITIS C VIRUS REPLICATION MERCK SHARP & DOHME CORP. (US) 2020-08-20 US disclosed
US-20200262836-A1 INHIBITORS OF HEPATITIS C VIRUS REPLICATION MERCK SHARP & DOHME CORP. (US) 2020-08-20 US disclosed
US-20190127365-A1 INHIBITORS OF HEPATITIS C VIRUS REPLICATION MERCK SHARP & DOHME CORP. (US) 2019-05-02 US disclosed
US-20190127365-A1 INHIBITORS OF HEPATITIS C VIRUS REPLICATION MERCK SHARP & DOHME CORP. (US) 2019-05-02 US disclosed
CN-108586369-A The preparation method of phenyl triaizine compounds and the preparation method of phenylpyridine compound 中国科学院长春应用化学研究所 2018-09-28 CN disclosed
WO-2010111483-A1 INHIBITORS OF HEPATITIS C VIRUS REPLICATION MERCK SHARP & DOHME CORP. (US) 2010-09-30 WO disclosed
WO-2010111483-A1 INHIBITORS OF HEPATITIS C VIRUS REPLICATION MERCK SHARP & DOHME CORP. (US) 2010-09-30 WO disclosed
US-6506747-B1 Method of treating an inflammatory disease which comprises administering to a patient in need of such treatment-a N-(4-(5-Ethyl-3-pyridin-3-yl-pyrazol-1-yl)phenyl)pyridine-3-carboxamide; BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. 2003-01-14 US disclosed
WO-1999062885-A1 SUBSTITUTED 1-(4-AMINOPHENYL)PYRAZOLES AND THEIR USE AS ANTI-INFLAMMATORY AGENTS BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) 1999-12-09 WO disclosed
US-4257952-A PSYCHOTROPIC DRUGS, ANALGESICS, ANTIHISTAMINES STERLING DRUG INC. (US) 1981-03-24 US disclosed
US-4172834-A ANALGESICS, ANTIHISTAMINES AND PSYCHOTROPIC AGENTS STERLING DRUG INC. (US) 1979-10-30 US disclosed
US-4062864-A ANALGESIC, PSYCHOTROPIC, ANTIHISTAMINE STERLING DRUG INC. (US) 1977-12-13 US disclosed
US-3979412-A Process for producing 3-anilino-5-pyrazolones FUJI PHOTO FILM CO., LTD. (JA) 1976-09-07 US disclosed
US-3959309-A ANALGESICS, PSYCHOTROPIC, ANTIHISTAMINE STERLING DRUG INC. (US) 1976-05-25 US disclosed
US-3933874-A Method for preparing of β-anilino-β-hydrazinoacrylates FUJI PHOTO FILM CO., LTD. (JA) 1976-01-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200262836-A1 INHIBITORS OF HEPATITIS C VIRUS REPLICATION HAVCR2, HCCS, EIF2AK2 SMN1; SMN2 4833/4885L3MBTL1 3665/4885HTT 4406/4885
US-11053243-B2 Inhibitors of hepatitis C virus replication HAVCR2, HCCS, EIF2AK2 SMN1; SMN2 4833/4885L3MBTL1 3665/4885HTT 4406/4885
US-20190127365-A1 INHIBITORS OF HEPATITIS C VIRUS REPLICATION HAVCR2, HCCS, EIF2AK2 SMN1; SMN2 4833/4885L3MBTL1 3665/4885HTT 4406/4885
US-20220356182-A1 INHIBITORS OF HEPATITIS C VIRUS REPLICATION HAVCR2, HCCS, EIF2AK2 SMN1; SMN2 4833/4885L3MBTL1 3665/4885HTT 4406/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.